Literature DB >> 25184924

Atypical lesions in relapsed leprosy.

Theisla Kely Azevedo Raiol1, Solange Emanuelle Volpato1, Patrícia de Barros Guimarães1, Maria Luciana Andrade de Almeida Lopes1, Daniela Mayumi Takano1, Jaci Maria Santana1.   

Abstract

Relapsed cases of leprosy are not common in patients treated regularly with the recommended polychemotherapeutical schemes. Relapses must be readily identified and distinguished from reactions. This article reports a clinical case of relapse in leprosy, with atypical and exuberant skin changes in patient treated for eleven years with a paucibacillary scheme.

Entities:  

Mesh：

Year:  2014        PMID： 25184924      PMCID： PMC4155963          DOI： 10.1590/abd1806-4841.20142989

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN： 0365-0596            Impact factor:   1.896


  5 in total

1.  Retreatment in leprosy: a case-control study.

Authors:  Ricardo Arraes Alencar Ximenes; Maria Eugênia Novinsk Gallo; Maria de Fátima de Medeiros Brito
Journal:  Rev Saude Publica       Date:  2007-08       Impact factor: 2.106

2.  Neural relapse in multibacillary leprosy 6 years after end of treatment.

Authors:  Leandra Oliveira Teixeira; Carlos Maximiliano Gaspar Carvalho Heil Silva; Hélcio Takeshi Akamatsu; Jaison Antônio Barreto; Cleverson Teixeira Soares
Journal:  An Bras Dermatol       Date:  2012 Mar-Apr       Impact factor: 1.896

3.  [Retrospective study on leprosy relapse in the State of Espírito Santo].

Authors:  Lucia Martins Diniz; Marilda Vieira Moreira; Marizete Altoé Puppin; Maria Leide Wand Del Rey de Oliveira
Journal:  Rev Soc Bras Med Trop       Date:  2009 Jul-Aug       Impact factor: 1.581

4.  [Relapse and drug resistance in leprosy].

Authors: 
Journal:  Rev Saude Publica       Date:  2011-06       Impact factor: 2.106

5.  Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT.

Authors:  V P Shetty; A V Wakade; S D Ghate; V V Pai; R R Ganapati; N H Antia
Journal:  Lepr Rev       Date:  2005-09       Impact factor: 0.537
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.